Loss of NSUN6 inhibits osteosarcoma progression by downregulating EEF1A2 expression and activation of Akt/mTOR signaling pathway via m<sup>5</sup>C methylation

Hu,Sang; Yang,Min; Xiao,Kangwen; Yang,Zhiqiang; Cai,Lin; Xie,Yuanlong; Wang,Linlong; Wei,Renxiong

doi:10.3892/etm.2023.12156

Loss of NSUN6 inhibits osteosarcoma progression by downregulating EEF1A2 expression and activation of Akt/mTOR signaling pathway via m⁵C methylation

Authors:
- Sang Hu
- Min Yang
- Kangwen Xiao
- Zhiqiang Yang
- Lin Cai
- Yuanlong Xie
- Linlong Wang
- Renxiong Wei
View Affiliations

Affiliations: Department of Spine Surgery and Musculoskeletal Tumor, Zhongnan Hospital of Wuhan University, Wuhan, Hubei 430071, P.R. China, Department of Orthopedics, Jingzhou Hospital Affiliated to Yangtze University, Jingzhou, Hubei 434020, P.R. China
Published online on: August 4, 2023 https://doi.org/10.3892/etm.2023.12156
Article Number: 457
Copyright: © Hu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

As an important 5‑methylcytidine (m⁵C) methyltransferase, NOP2/Sun RNA methyltransferase family member 6 (NSUN6) has been reported to play an important role in the progression of several diseases. However, the role of NSUN6 in the progression of osteosarcoma (OS) remains unclear. This study aimed to identify the role of NSUN6 in the progression of OS and clarify the potential molecular mechanism. The present study discovered that NSUN6 was upregulated in OS and a higher NSUN6 expression was a strong indicator for poorer prognosis of patients with OS. In addition, the loss of NSUN6 led to reduced proliferation, migration and invasion of OS cells. Through bioinformatics analysis, RNA immunoprecipitation (RIP) and methylated RIP assays, eukaryotic elongation factor 1 α‑2 (EEF1A2) was identified and validated as a potential target of NSUN6 in OS. Mechanistically, the expression of EEF1A2 was significantly suppressed following NSUN6 knockdown due to reduced EEF1A2 mRNA stability in an m⁵C‑dependent manner. Meanwhile, NSUN6 deficiency inhibited m⁵C‑dependent activation of Akt/mTOR signaling pathway. In addition, genetic overexpression of EEF1A2 or pharmacological activation of the Akt signaling pathway counteracted the suppressive effects of NSUN6 deficiency on the proliferation, invasion and migration of OS cells. The current findings suggested that NSUN6 may serve as a potential therapeutic target for OS treatment.

View Figures

View References

1	Durfee RA, Mohammed M and Luu HH: Review of osteosarcoma and current management. Rheumatol Ther. 3:221–243. 2016.PubMed/NCBI View Article : Google Scholar
2	Li S, Zhang H, Liu J and Shang G: Targeted therapy for osteosarcoma: A review. J Cancer Res Clin Oncol: Feb 18, 2023 (Epub ahead of print).
3	Chen S, Li Y, Zhi S, Ding Z, Wang W, Peng Y, Huang Y, Zheng R, Yu H, Wang J, et al: WTAP promotes osteosarcoma tumorigenesis by repressing HMBOX1 expression in an m⁶A-dependent manner. Cell Death Dis. 11(659)2020.PubMed/NCBI View Article : Google Scholar
4	Xie L, Yao Z, Zhang Y, Li D, Hu F, Liao Y, Zhou L, Zhou Y, Huang Z, He Z, et al: Deep RNA sequencing reveals the dynamic regulation of miRNA, lncRNAs, and mRNAs in osteosarcoma tumorigenesis and pulmonary metastasis. Cell Death Dis. 9(772)2018.PubMed/NCBI View Article : Google Scholar
5	Jafari F, Javdansirat S, Sanaie S, Naseri A, Shamekh A, Rostamzadeh D and Dolati S: Osteosarcoma: A comprehensive review of management and treatment strategies. Ann Diagn Pathol. 49(151654)2020.PubMed/NCBI View Article : Google Scholar
6	Wang B, Yao L, Dong Y, Liu J and Wu J: LncRNA PCED1B-AS1 knockdown inhibits osteosarcoma via methylation-mediated miR-10a downregulation. J Orthop Surg Res. 17(464)2022.PubMed/NCBI View Article : Google Scholar
7	Tsukamoto S, Righi A, Kido A, Honoki K, Tanaka Y, Fujii H, Mavrogenis AF, Tanaka Y and Errani C: Effect of adjuvant chemotherapy on periosteal osteosarcoma: A systematic review. Jpn J Clin Oncol. 52:896–904. 2022.PubMed/NCBI View Article : Google Scholar
8	Liu W, Zhao Y, Wang G, Feng S, Ge X, Ye W, Wang Z, Zhu Y, Cai W, Bai J and Zhou X: TRIM22 inhibits osteosarcoma progression through destabilizing NRF2 and thus activation of ROS/AMPK/mTOR/autophagy signaling. Redox Biol. 53(102344)2022.PubMed/NCBI View Article : Google Scholar
9	Lin H, Chen X, Zhang C, Yang T, Deng Z, Song Y, Huang L, Li F, Li Q, Lin S and Jin D: EF24 induces ferroptosis in osteosarcoma cells through HMOX1. Biomed Pharmacother. 136(111202)2021.PubMed/NCBI View Article : Google Scholar
10	Xiao X, Wang W, Li Y, Yang D, Li X, Shen C, Liu Y, Ke X, Guo S and Guo Z: HSP90AA1-mediated autophagy promotes drug resistance in osteosarcoma. J Exp Clin Cancer Res. 37(201)2018.PubMed/NCBI View Article : Google Scholar
11	Liu Q and Wang K: The induction of ferroptosis by impairing STAT3/Nrf2/GPx4 signaling enhances the sensitivity of osteosarcoma cells to cisplatin. Cell Biol Int. 43:1245–1256. 2019.PubMed/NCBI View Article : Google Scholar
12	Dong S, Wu Y, Liu Y, Weng H and Huang H: N⁶ -methyladenosine steers RNA metabolism and regulation in cancer. Cancer Commun (Lond). 41:538–559. 2021.PubMed/NCBI View Article : Google Scholar
13	Kumar VE, Nambiar R, De Souza C, Nguyen A, Chien J and Lam KS: Targeting epigenetic modifiers of tumor plasticity and cancer stem cell behavior. Cells. 11(1403)2022.PubMed/NCBI View Article : Google Scholar
14	Nacev BA, Jones KB, Intlekofer AM, Yu JSE, Allis CD, Tap WD, Ladanyi M and Nielsen TO: The epigenomics of sarcoma. Nat Rev Cancer. 20:608–623. 2020.PubMed/NCBI View Article : Google Scholar
15	Yang B, Wang JQ, Tan Y, Yuan R, Chen ZS and Zou C: RNA methylation and cancer treatment. Pharmacol Res. 174(105937)2021.PubMed/NCBI View Article : Google Scholar
16	Han X, Wang M, Zhao YL, Yang Y and Yang YG: RNA methylations in human cancers. Semin Cancer Biol. 75:97–115. 2021.PubMed/NCBI View Article : Google Scholar
17	Dominissini D and Rechavi G: 5-methylcytosine mediates nuclear export of mRNA. Cell Res. 27:717–719. 2017.PubMed/NCBI View Article : Google Scholar
18	Garcia-Vilchez R, Sevilla A and Blanco S: Post-transcriptional regulation by cytosine-5 methylation of RNA. Biochim Biophys Acta Gene Regul Mech. 1862:240–252. 2019.PubMed/NCBI View Article : Google Scholar
19	Xue C, Zhao Y and Li L: Advances in RNA cytosine-5 methylation: Detection, regulatory mechanisms, biological functions and links to cancer. Biomark Res. 8(43)2020.PubMed/NCBI View Article : Google Scholar
20	Yang X, Yang Y, Sun BF, Chen YS, Xu JW, Lai WY, Li A, Wang X, Bhattarai DP, Xiao W, et al: 5-methylcytosine promotes mRNA export-NSUN2 as the methyltransferase and ALYREF as an m⁵C reader. Cell Res. 27:606–625. 2017.PubMed/NCBI View Article : Google Scholar
21	Chellamuthu A and Gray SG: The RNA methyltransferase NSUN2 and its potential roles in cancer. Cells. 9(1758)2020.PubMed/NCBI View Article : Google Scholar
22	Zhang Q, Liu F, Chen W, Miao H, Liang H, Liao Z, Zhang Z and Zhang B: The role of RNA m⁵C modification in cancer metastasis. Int J Biol Sci. 17:3369–3380. 2021.PubMed/NCBI View Article : Google Scholar
23	Sun Z, Xue S, Zhang M, Xu H, Hu X, Chen S, Liu Y, Guo M and Cui H: Aberrant NSUN2-mediated m⁵C modification of H19 lncRNA is associated with poor differentiation of hepatocellular carcinoma. Oncogene. 39:6906–6919. 2020.PubMed/NCBI View Article : Google Scholar
24	Chen X, Li A, Sun BF, Yang Y, Han YN, Yuan X, Chen RX, Wei WS, Liu Y, Gao CC, et al: 5-methylcytosine promotes pathogenesis of bladder cancer through stabilizing mRNAs. Nat Cell Biol. 21:978–990. 2019.PubMed/NCBI View Article : Google Scholar
25	Gao Y, Wang Z, Zhu Y, Zhu Q, Yang Y, Jin Y, Zhang F, Jiang L, Ye Y, Li H, et al: NOP2/Sun RNA methyltransferase 2 promotes tumor progression via its interacting partner RPL6 in gallbladder carcinoma. Cancer Sci. 110:3510–3519. 2019.PubMed/NCBI View Article : Google Scholar
26	Hu Y, Chen C, Tong X, Chen S, Hu X, Pan B, Sun X, Chen Z, Shi X, Hu Y, et al: NSUN2 modified by SUMO-2/3 promotes gastric cancer progression and regulates mRNA m5C methylation. Cell Death Dis. 12(842)2021.PubMed/NCBI View Article : Google Scholar
27	Mei L, Shen C, Miao R, Wang JZ, Cao MD, Zhang YS, Shi LH, Zhao GH, Wang MH, Wu LS and Wei JF: RNA methyltransferase NSUN2 promotes gastric cancer cell proliferation by repressing p57^Kip2 by an m⁵C-dependent manner. Cell Death Dis. 11(270)2020.PubMed/NCBI View Article : Google Scholar
28	Yang R, Liang X, Wang H, Guo M, Shen H, Shi Y, Liu Q, Sun Y, Yang L and Zhan M: The RNA methyltransferase NSUN6 suppresses pancreatic cancer development by regulating cell proliferation. Ebiomedicine. 63(103195)2021.PubMed/NCBI View Article : Google Scholar
29	Awah CU, Winter J, Mazdoom CM and Ogunwobi OO: NSUN6, an RNA methyltransferase of 5-mC controls glioblastoma response to temozolomide (TMZ) via NELFB and RPS6KB2 interaction. Cancer Biol Ther. 22:587–597. 2021.PubMed/NCBI View Article : Google Scholar
30	Blaze J, Navickas A, Phillips HL, Heissel S, Plaza-Jennings A, Miglani S, Asgharian H, Foo M, Katanski CD, Watkins CP, et al: Neuronal Nsun2 deficiency produces tRNA epitranscriptomic alterations and proteomic shifts impacting synaptic signaling and behavior. Nat Commun. 12(4913)2021.PubMed/NCBI View Article : Google Scholar
31	Lu L, Zhu G, Zeng H, Xu Q and Holzmann K: High tRNA Transferase NSUN2 Gene expression is associated with poor prognosis in head and neck squamous carcinoma. Cancer Invest. 36:246–253. 2018.PubMed/NCBI View Article : Google Scholar
32	Haag S, Warda AS, Kretschmer J, Gunnigmann MA, Hobartner C and Bohnsack MT: NSUN6 is a human RNA methyltransferase that catalyzes formation of m5C72 in specific tRNAs. RNA. 21:1532–1543. 2015.PubMed/NCBI View Article : Google Scholar
33	Zhou L, Yang C, Zhang N, Zhang X, Zhao T and Yu J: Silencing METTL3 inhibits the proliferation and invasion of osteosarcoma by regulating ATAD2. Biomed Pharmacother. 125(109964)2020.PubMed/NCBI View Article : Google Scholar
34	Zhou X, Yang Y, Li Y, Liang G, Kang D, Zhou B and Li Q: METTL3 contributes to osteosarcoma progression by increasing DANCR mRNA stability via m6A modification. Front Cell Dev Biol. 9(784719)2021.PubMed/NCBI View Article : Google Scholar
35	Jiang R, Dai Z, Wu J, Ji S, Sun Y and Yang W: METTL3 stabilizes HDAC5 mRNA in an m⁶A-dependent manner to facilitate malignant proliferation of osteosarcoma cells. Cell Death Discov. 8(179)2022.PubMed/NCBI View Article : Google Scholar
36	Yang M, Wei R, Zhang S, Hu S, Liang X, Yang Z, Zhang C, Zhang Y, Cai L and Xie Y: NSUN2 promotes osteosarcoma progression by enhancing the stability of FABP5 mRNA via m⁵C methylation. Cell Death Dis. 14(125)2023.PubMed/NCBI View Article : Google Scholar
37	Yang J, Tang J, Li J, Cen Y, Chen J and Dai G: Effect of activation of the Akt/mTOR signaling pathway by EEF1A2 on the biological behavior of osteosarcoma. Ann Transl Med. 9(158)2021.PubMed/NCBI View Article : Google Scholar
38	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001.PubMed/NCBI View Article : Google Scholar
39	Selmi T, Hussain S, Dietmann S, Heiβ M, Borland K, Flad S, Carter JM, Dennison R, Huang YL, Kellner S, et al: Sequence- and structure-specific cytosine-5 mRNA methylation by NSUN6. Nucleic Acids Res. 49:1006–1022. 2021.PubMed/NCBI View Article : Google Scholar
40	Wu S, Zhang S, Wu X and Zhou X: m⁶A RNA methylation in cardiovascular diseases. Mol Ther. 28:2111–2119. 2020.PubMed/NCBI View Article : Google Scholar
41	Shen H, Lan Y, Zhao Y, Shi Y, Jin J and Xie W: The emerging roles of N6-methyladenosine RNA methylation in human cancers. Biomark Res. 8(24)2020.PubMed/NCBI View Article : Google Scholar
42	Wang S, Sun C, Li J, Zhang E, Ma Z, Xu W, Li H, Qiu M, Xu Y, Xia W, et al: Roles of RNA methylation by means of N⁶-methyladenosine (m⁶A) in human cancers. Cancer Lett. 408:112–120. 2017.PubMed/NCBI View Article : Google Scholar
43	Shinoda S, Kitagawa S, Nakagawa S, Wei FY, Tomizawa K, Araki K, Araki M and Suzuki T and Suzuki T: Mammalian NSUN2 introduces 5-methylcytidines into mitochondrial tRNAs. Nucleic Acids Res. 47:8734–8745. 2019.PubMed/NCBI View Article : Google Scholar
44	Auxilien S, Guerineau V, Szweykowska-Kulinska Z and Golinelli-Pimpaneau B: The human tRNA m (5) C methyltransferase Misu is multisite-specific. RNA Biol. 9:1331–1338. 2012.PubMed/NCBI View Article : Google Scholar
45	Hussain S: The emerging roles of cytosine-5 methylation in mRNAs. Trends Genet. 37:498–500. 2021.PubMed/NCBI View Article : Google Scholar
46	Xu X, Zhang Y, Zhang J and Zhang X: NSUN2 promotes cell migration through methylating autotaxin mRNA. J Biol Chem. 295:18134–18147. 2020.PubMed/NCBI View Article : Google Scholar
47	Su J, Wu G, Ye Y, Zhang J, Zeng L, Huang X, Zheng Y, Bai R, Zhuang L, Li M, et al: NSUN2-mediated RNA 5-methylcytosine promotes esophageal squamous cell carcinoma progression via LIN28B-dependent GRB2 mRNA stabilization. Oncogene. 40:5814–5828. 2021.PubMed/NCBI View Article : Google Scholar
48	Jia L, Ge X, Du C, Chen L, Zhou Y, Xiong W, Xiang J, Li G, Xiao G, Fang L and Li Z: EEF1A2 interacts with HSP90AB1 to promote lung adenocarcinoma metastasis via enhancing TGF-β/SMAD signalling. Br J Cancer. 124:1301–1311. 2021.PubMed/NCBI View Article : Google Scholar
49	Losada A, Munoz-Alonso MJ, Martinez-Diez M, Gago F, Dominguez JM, Martinez-Leal JF and Galmarini CM: Binding of eEF1A2 to the RNA-dependent protein kinase PKR modulates its activity and promotes tumour cell survival. Br J Cancer. 119:1410–1420. 2018.PubMed/NCBI View Article : Google Scholar
50	Sun Y, Du C, Wang B, Zhang Y, Liu X and Ren G: Up-regulation of eEF1A2 promotes proliferation and inhibits apoptosis in prostate cancer. Biochem Biophys Res Commun. 450:1–6. 2014.PubMed/NCBI View Article : Google Scholar
51	Lee MH, Choi BY, Cho YY, Lee SY, Huang Z, Kundu JK, Kim MO, Kim DJ, Bode AM, Surh YJ, et al: Tumor suppressor p16 (INK4a) inhibits cancer cell growth by downregulating eEF1A2 through a direct interaction. J Cell Sci. 126:1744–1752. 2013.PubMed/NCBI View Article : Google Scholar